<!doctype html>
<html lang="en">
<head>
<meta charset="utf-8" />


<script type="text/javascript" src="https://code.jquery.com/jquery-1.11.3.min.js"></script>
<script type="text/javascript" src="/js/jquery.cookie.js"></script>
<script type="text/javascript" src="/js/md5.js"></script>
<script type="text/javascript" src="/js/bpopup-0.11.0.min.js"></script>
<style>
.keytext{
	display:hidden;
	font-size:13px;
	margin: 0 0 20px;
}
</style>



<title>HB 2831 Text</title>
<meta name="description" content="Bill Status - Bill Text">
<meta name="keywords" content="Legislation, Bill, bill text, West Virginia Bills, West Virginia Bill, West Virginia Legislature, West Virginia, Legislature, WV">
<LINK REL="SHORTCUT ICON" HREF="../images/home_link.gif">

<style type="text/css">
	body,p {margin: 10px 0 0 15px !important;
	padding: 0px !important;
	font-size: 100% !important;
	font: inherit !important;
	font-family: Arial, Helvetica, sans-serif !important;
	vertical-align: baseline !important;
}
#pod-icon{
padding: 5px 5px 12px 10px;
width: 460px;
border: 1px solid black;
border-radius: 10px;
margin-top:8px;
}
#pod-popup{
    background-color:#fff;
    border-radius:5px;
    color:#000;
    display:none; 
    padding:20px;
    min-width:400px;
    min-height: 180px;
}
#pod-popup h3{padding: 0px 10px 10px 0px}
.pod-meta{width:400px;font-size:15px;background-color:#eee;padding:5px;margin:0 0 4px;float:left}
.b-close{
    cursor:pointer;
    position:absolute;
    right:10px;
    top:5px;
}
.b-close img{
width: 40px;
height: auto;
}
 span {font-family: Arial, Helvetica, sans-serif !important;}
 
 p {text-indent: 15px !important;
 line-height:24px !important;}
 .meta-input{
 float:right;
 width:300px;
 font-size:14px;
 }
 #pod-minus{
 margin-left:5px!important;
 width:40px;height:auto
 }
 #pod-plus{
 margin:10px 0 0 0;
 width:40px;
 height:auto
 }
 #pod-count{
 font-size:15px;
 padding:6px;
 }
 #pod-ok{
 width:28px;
 height:auto;
 margin-top:5px;
 }
 #pod-go{
 float:right;
 }
 .pod-input-error{
 border:2px solid red;
 }
 .pod-row{
 vertical-align:middle;
 height:24px;
 padding:0;
 margin:2px 0 4px;
 }
 .del-pod{
 float:left;
 margin:0 4px 0}
</style>

<link rel="stylesheet" type="text/css" href="../styletest1.css" media="screen">
<link rel="stylesheet" type="text/css" href="../stylebillstatus.css" media="screen">
<link rel="stylesheet" type="text/css" href="../printbstat.css" media="print">


<meta name="viewport" content="width=device-width, initial-scale=1">
<script async src="https://cse.google.com/cse.js?cx=5c3144a0752ec82d3"></script>
<script type="text/javascript">

function MM_reloadPage(init) {  //reloads the window if Nav4 resized
  if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
    document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
  else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
function _autoLayers() { //v1.4 by PVII
 var g,b,k,f,args=_autoLayers.arguments;a=parseInt(args[0]);if(isNaN(a))a=0;
 if(!document.setc){c=new Array();document.setc=true;for(var u=0;u<10;u++){
 c[u]=new Array();}}for(k=0;k<c[a].length;k++){if((g=MM_findObj(c[a][k]))!=null){
 b=(document.layers)?g:g.style;b.visibility="hidden";}}for(k=1;k<args.length;k++){
 if((g=MM_findObj(args[k]))!=null){b=(document.layers)?g:g.style;b.visibility="visible";f=false;
 for(var j=0;j<c[a].length;j++){if(args[k]==c[a][j]) {f=true;}}
 if(!f){c[a][c[a].length++]=args[k];}}}
}
function _Snap() { //v2.65 by PVII
 var x,y,ox,bx,oy,p,tx,a,b,k,d,da,e,el,tw,q0,xx,yy,w1,pa='px',args=_Snap.arguments;a=parseInt(a);
 if(document.layers||window.opera){pa='';}for(k=0;k<(args.length);k+=4){
 if((g=MM_findObj(args[k]))!=null){if((el=MM_findObj(args[k+1]))!=null){
 a=parseInt(args[k+2]);b=parseInt(args[k+3]);x=0;y=0;ox=0;oy=0;p="";tx=1;
 da="document.all['"+args[k]+"']";if(document.getElementById){
 d="document.getElementsByName('"+args[k]+"')[0]";if(!eval(d)){
 d="document.getElementById('"+args[k]+"')";if(!eval(d)){d=da;}}
 }else if(document.all){d=da;}if(document.all||document.getElementById){while(tx==1){
 p+=".offsetParent";if(eval(d+p)){x+=parseInt(eval(d+p+".offsetLeft"));y+=parseInt(eval(d+p+".offsetTop"));
 }else{tx=0;}}ox=parseInt(g.offsetLeft);oy=parseInt(g.offsetTop);tw=x+ox+y+oy;
 if(tw==0||(navigator.appVersion.indexOf("MSIE 4")>-1&&navigator.appVersion.indexOf("Mac")>-1)){
  ox=0;oy=0;if(g.style.left){x=parseInt(g.style.left);y=parseInt(g.style.top);}else{
  w1=parseInt(el.style.width);bx=(a<0)?-5-w1:-10;a=(Math.abs(a)<1000)?0:a;b=(Math.abs(b)<1000)?0:b;
  x=document.body.scrollLeft+event.clientX+bx;y=document.body.scrollTop+event.clientY;}}
 }else if(document.layers){x=g.x;y=g.y;q0=document.layers,dd="";for(var s=0;s<q0.length;s++){
  dd='document.'+q0[s].name;if(eval(dd+'.document.'+args[k])){x+=eval(dd+'.left');y+=eval(dd+'.top');
  break;}}}e=(document.layers)?el:el.style;xx=parseInt(x+ox+a),yy=parseInt(y+oy+b);
 if(navigator.appVersion.indexOf("MSIE 5")>-1 && navigator.appVersion.indexOf("Mac")>-1){
  xx+=parseInt(document.body.leftMargin);yy+=parseInt(document.body.topMargin);}
 e.left=xx+pa;e.top=yy+pa;}}}
}
function _hideDiv(evt) { //v1.3 by PVII
 var b,relT,mT=false; 
 if(document.layers){b=evt.target;if(b.aHide){
  b.visibility="hidden";}else{routeEvent(evt);}
 }else if(document.all&&!window.opera){b=event.srcElement;
  while(b!=null){if(b.tagName=="DIV" && b.ahD){mT=true;break;}b=b.parentElement;}
  if(!b.contains(event.toElement)){b.style.visibility="hidden";}
 }else if(document.getElementById){b=evt.currentTarget;relT=evt.relatedTarget;
  while(relT!=null){if(b==relT){mT=true;break;}
  relT=relT.parentNode;}if(!mT){b.style.visibility="hidden";}}
}
function _autoHide() { //v1.3 by PVII
 var i,g,args=_autoHide.arguments;
 for(i=0;i<args.length;i++){if((g=MM_findObj(args[i]))!=null){
  g.aHide=true;if(document.layers){
  g.captureEvents(Event.MOUSEOUT);}g.onmouseout=_hideDiv;g.ahD=true;}}
}
function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}
function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
function MM_preloadImages() { //v3.0
 var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
   var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
   if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}
 
//  function hov(loc,cls){
//  if(loc.className)
//  loc.className=cls;}
//-->

function init() {
_autoHide('subs1','subs2','subs3','subs4','subs5','subs6','subs7','subs8')
} 

window.onload= init;
</script>


<!-- Google tag (gtag.js) edited 12-11-2023 JDT//DO NOT TOUCH-->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-EED2LTLF4G "></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-EED2LTLF4G ');
</script>
<!-- edited 12-11-2023 JDT//DO NOT TOUCH-->

</head>
<body>
<div id="navskip"><a href="#main" name="begin">skip navigation</a></div>

<div id="mainsearch">
	
	
		<div class="gcse-searchbox-only" data-resultsUrl="https://www.wvlegislature.gov/search.cfm" data-enableHistory="true"></div>
	
</div>


<div id="logo"><img src="/images/header.png" usemap="#m_header" alt="header" name="header" width="878" height="80"  onMouseOver="_autoLayers(0)" >
<map name="m_header"><area shape="rect" coords="126,10,515,53" href="/index.cfm" alt="header"></map></div>

<div id="trigger1"><a href="#" onKeyPress="_autoLayers(0,'subs1');_Snap('mb1','subs1',1,22)" onMouseOver="_autoLayers(0,'subs1');_Snap('mb1','subs1',1,22)">SENATE</a></div>
<div id="subs1" class="submenus">
<a href="/Senate1/president.cfm">PRESIDENT</a>
<a href="/Senate1/roster.cfm">SENATORS</a>
<a href="/committees/senate/main.cfm">COMMITTEES</a>
<a href="http://www.wvlegislature.gov/live.cfm">VIDEO/AUDIO</a>
<a href="/redistricting.cfm">DISTRICT MAPS</a>
<a href="/Senate1/clerk.cfm">SENATE CLERK</a>
<a href="/Senate1/rules.cfm">SENATE RULES</a>
</div>

<div id="trigger2"><a href="#"  onKeyPress="_autoLayers(0,'subs2');_Snap('mb2','subs2',0,22)" onMouseOver="_autoLayers(0,'subs2');_Snap('mb2','subs2',0,22)">HOUSE</a></div>
<div id="subs2" class="submenus">
<a href="/House/speaker.cfm">SPEAKER</a>
<a href="/House/roster.cfm">DELEGATES</a>
<a href="/committees/house/main.cfm">COMMITTEES</a>
<a href="http://www.wvlegislature.gov/live.cfm">VIDEO/AUDIO</a>
<a href="/redistricting.cfm">DISTRICT MAPS</a>
<a href="/House/clerk.cfm">HOUSE CLERK</a>
<a href="/House/rules.cfm">HOUSE RULES</a>
<a href="//house.wvlegislature.gov/">HOUSE STAFF</a>
</div>

<div id="trigger3"><a href="#"  onKeyPress="_autoLayers(0,'subs3');_Snap('mb3','subs3',1,22)" onMouseOver="_autoLayers(0,'subs3');_Snap('mb3','subs3',1,22)">JOINT</a></div>
<div id="subs3" class="submenus">
<a href="/committees/interims/interims.cfm">INTERIM COMMITTEES</a>
<a href="/Joint/administrator.cfm">LEGISLATIVE ADMINISTRATOR</a>
<a href="/Joint/legis_services.cfm">LEGISLATIVE SERVICES DIVISION</a>
<a href="/Joint/legisinfo.cfm">PUBLIC INFORMATION</a>
<a href="/Joint/computercenter.cfm">LEGISLATIVE AUTOMATED SYSTEMS DIVISION</a>
<a href="/Joint/legislative-auditor.cfm">LEGISLATIVE AUDITOR'S OFFICE</a>
<a href="/Joint/perd.cfm">PERFORMANCE EVALUATION & RESEARCH DIVISION</a>
<a href="/Joint/postaudit.cfm">POST AUDIT DIVISION</a>
<a href="/Joint/budget.cfm">BUDGET DIVISION</a>
<a href="/Joint/fiscal-regulatory.cfm">REGULATORY AND FISCAL AFFAIRS DIVISION</a>
<a href="//claims.wvlegislature.gov/">CLAIMS COMMISSION</a>
<a href="/Joint/victims.cfm">CRIME VICTIMS</a>
<a href="/Joint/rule_making.cfm">RULE-MAKING REVIEW</a>
<a href="/Joint/csi.cfm">SPECIAL INVESTIGATIONS</a>
<a href="/Interims/judicial_comp.cfm">JUDICIAL COMP. COMMISSION</a>
<a href="/Joint/rules.cfm">JOINT RULES</a>
<a href="//staff.wvlegislature.gov/"><strong>STAFF INFO</strong></a></div>


<div id="trigger4"><a href="#" onKeyPress="_autoLayers(0,'subs4');_Snap('mb4','subs4',1,22)" onMouseOver="_autoLayers(0,'subs4');_Snap('mb4','subs4',1,22)">BILL STATUS</a></div>
<div id="subs4" class="submenus">
<a href="/Bill_Status/bill_status.cfm">BILL STATUS</a>
<a href="/billstatus_personalized/persbills_login.cfm">BILL TRACKING</a></div>

<div id="trigger5"><a href="#" onKeyPress="_autoLayers(0,'subs5');_Snap('mb5','subs5',1,22)" onMouseOver="_autoLayers(0,'subs5');_Snap('mb5','subs5',1,22)">STATE LAW</a></div>
<div id="subs5" class="submenus">

<a href="//code.wvlegislature.gov">WEST VIRGINIA CODE</a>
<a href="/Educational/publications.cfm#acts">ACTS OF THE LEGISLATURE</a>
<a href="/Educational/publications/WVCode1931.cfm">CODE OF 1931</a>
<a href="/WVCODE/WV_CON.cfm">WV CONSTITUTION</a>
<a href="/WVCODE/US_CON.cfm">US CONSTITUTION</a>
</div>

<div id="trigger6"><a href="#"   onKeyPress="_autoLayers(0,'subs6');_Snap('mb6','subs6',1,22)" onMouseOver="_autoLayers(0,'subs6');_Snap('mb6','subs6',1,22)">REPORTS</a></div>
<div id="subs6" class="submenus">

<a href="/Reports/Agency_Reports/agencylist_all.cfm">AGENCY REPORTS</a>
<a href="/SAGA/Agency.cfm">AGENCY GRANT AWARDS</a>
<a href="/Joint/PERD/reports.cfm">PERFORMANCE EVALUATIONS</a>
<a href="/Joint/Postaudit/reports.cfm">POST AUDITS</a>

</div>

<div id="trigger7"><a href="#"  onKeyPress="_autoLayers(0,'subs7');_Snap('mb7','subs7',1,22)" onMouseOver="_autoLayers(0,'subs7');_Snap('mb7','subs7',1,22)">EDUCATIONAL</a></div>
<div id="subs7" class="submenus">
<a href="/Educational/citizens/guide.cfm">CITIZEN&#8217;S GUIDE</a>
<a href="/Educational/internship.cfm">INTERNSHIP PROGRAM</a>
<a href="//home.wvlegislature.gov/page-program/">PAGE PROGRAM</a>

<a href="/Educational/publications.cfm">PUBLICATIONS</a>
<a href="/photos" title="Visit the Legislature's Capitol Photo Gallery">PHOTO GALLERY</a>
<a href="/Educational/Capitol_History/cap.cfm">CAPITOL HISTORY</a>
<a href="/Educational/Bill_Becomes_Law/Bill_Becomes_Law.cfm">HOW A BILL BECOMES LAW</a>
<!--<a href="/Educational/Kids_Page/kids.html">Kids&#8217; Page</a>--></div>

<div id="trigger8"><a href="#"  onKeyPress="_autoLayers(0,'subs8');_Snap('mb8','subs8',1,22)" onMouseOver="_autoLayers(0,'subs8');_Snap('mb8','subs8',1,22)">CONTACT</a></div>
<div id="subs8" class="submenus">
<a href="/Senate1/roster.cfm">SENATE ROSTER</a>
<a href="/House/roster.cfm">HOUSE ROSTER</a>
<!--<a href="/Contact/capmail.cfm">All Members List</a>-->
<a href="/Joint/legisinfo.cfm">PUBLIC INFO.</a>
<a href="/News_release/news.cfm">NEWS RELEASES</a>
<a href="/Contact/Links/links.cfm">HELPFUL LINKS</a></div>

<div id="triggerhome">
<img name="Home" src="/images/Home.gif" usemap="#m_Home" alt="home" height="21" width="26"></div>

<map name="m_Home">
<area shape="rect" coords="0,0,26,21" href="/index.cfm" alt="home" onMouseOut="MM_swapImage('Home','','/images/Home.gif',1);"  onMouseOver="MM_swapImage('Home','','/images/Home_f2.gif',1);_autoLayers(0)">
</map>

<a name="main" id="main"></a>

<div id="wrapper">

<span id='billversion' class="boldtxthead">
Introduced Version

</span>




<span class="billemail">


<a href="bills_history.cfm?year=2025&sessiontype=RS&input=2831"> 
House Bill 2831 History</a>


</span><br>

<div class='noprint' id='pod-icon' data-qty='0' data-version='' data-remoteip='172.174.221.230' data-billchamber='House' data-year='2025' data-billnumber='Bill 2831'>
</div>

<br>





<span class="billemail">

<font size="-2"><b></b>&nbsp;</font>
  

 <!--EMAIL-->&nbsp;|&nbsp;<a href="mailto:?subject=HB 2831 - Creating the Prescription Drug Affordability Board&amp;body=https://www.wvlegislature.gov/bill_status/bills_text.cfm?billdoc=hb2831+intr.htm%26yr=2025%26sesstype=RS%26billtype=B%26houseorig=H%26i=2831"><img src="../images/mail_icon.gif"> Email</a><!--EMAIL-->

</span>




<hr noshade color="#000000" width="880px" size="1px" align="left">



 <div class='keytext'>Key: <span style='color:green'>Green</span> = existing Code. <span style='color:red'>Red</span> = new code to be enacted</div>
<div class='textcontainer'>




	<style type="text/css">
		.cs4B09651A{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:2}
		.cs9C2C975F{color:#000000;background-color:transparent;font-family:Arial;font-size:22pt;font-weight:bold;font-style:normal;}
		.csDC685BE1{text-align:center;text-indent:0pt;margin:0pt 0pt 48pt 0pt;line-height:2}
		.cs3BC7FF6A{color:#000000;background-color:transparent;font-family:Arial;font-size:18pt;font-weight:bold;font-style:normal;text-transform:uppercase;}
		.csA79677C3{color:#000000;background-color:transparent;font-family:Arial;font-size:18pt;font-weight:bold;font-style:normal;}
		.csF36D445B{text-align:center;text-indent:0pt;margin:0pt 0pt 18pt 0pt;line-height:2}
		.csCA3E41D9{text-align:center;text-indent:0pt;margin:0pt 90pt 6pt 90pt;line-height:2}
		.csBB3ABC40{color:#000000;background-color:transparent;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;font-variant:small-caps;}
		.csBA891411{text-align:center;text-indent:0pt;margin:0pt 90pt 0pt 90pt;line-height:2}
		.csA9049697{color:#000000;background-color:transparent;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;}
		.cs488BC2{text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;line-height:2;page-break-before:always}
		.csE736517A{color:#000000;background-color:transparent;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;}
		.cs55F91DED{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:2}
		.cs50A3B802{color:#000000;background-color:transparent;font-family:Arial;font-size:11pt;font-weight:normal;font-style:italic;}
		.cs9B0A970F{color:#000000;background-color:transparent;font-family:Arial;font-size:12pt;font-weight:bold;font-style:normal;text-decoration: underline;}
		.cs5BCBAEC9{color:#000000;background-color:transparent;font-family:Arial;font-size:11pt;font-weight:bold;font-style:normal;text-decoration: underline;}
		.cs45E53620{text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 0pt;line-height:2}
		.csF2E808A1{color:#000000;background-color:transparent;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-decoration: underline;}
		.cs5AD36D8A{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:2}
		.cs13A1C9D2{color:#000000;background-color:transparent;font-family:Arial;font-size:11pt;font-weight:normal;font-style:italic;text-decoration: underline;}
		.csDE8452F9{text-align:justify;text-indent:0pt;margin:0pt 36pt 11pt 36pt}
		.csAD690475{color:#000000;background-color:transparent;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;}
	</style>
	<p class="cs4B09651A"><span class="cs9C2C975F">WEST VIRGINIA LEGISLATURE</span></p><p class="csDC685BE1"><span class="cs3BC7FF6A">2025 </span><span class="csA79677C3">REGULAR SESSION</span></p><p class="cs4B09651A"><span class="csA79677C3">Introduced</span></p><p class="csF36D445B"><span class="cs9C2C975F">House Bill 2831</span></p><p class="csCA3E41D9"><span class="csBB3ABC40">By Delegates Young and Lewis</span></p><p class="csBA891411"><span class="csA9049697">[Introduced February 24, 2025; referred to the Committee on Health and Human Resources then Finance]</span></p><p class="cs488BC2"><span class="csE736517A">A BILL to amend the Code of West Virginia, 1931, as amended, by adding a new article, designated &sect;16-8C-1, &sect;16-8C-2, &sect;16-8C-3, &sect;16-8C-4, &sect;16-8C-5, &sect;16-8C-6, &sect;16-8C-7, &sect;16-8C-8, &sect;16-8C-9, &sect;16-8C-10, &sect;16-8C-11, &sect;16-8C-12, &sect;16-8C-13, &sect;16-8C-14, &sect;16-8C-15, and &sect;16-8C-16, relating to establishing the West Virginia Prescription Drug Affordability Board; providing definitions; providing for the creation of a Board and the composition, compensation, and duties associated with the Board; providing for the creation of a stakeholder council and the composition, and duties associated with the Council; &nbsp;providing disclosures of conflicts of interest and requiring adherence to the Ethics Act; requiring a study and report on transparency data on prescription drug products; providing a cost review of prescription drug products with affordability challenges; requiring confidentiality; establishing a fund; providing for enforcement; clarifying drug products eligible; providing remedies; and listing all report requirements.</span></p><p class="cs55F91DED"><span class="cs50A3B802">Be it enacted by the Legislature of West Virginia:</span></p><p class="cs55F91DED"><span class="cs9B0A970F">ARTICLE 8C. WEST VIRGINIA PRESCRIPTION DRUG AFFORDABILITY BOARD.</span></p><p class="cs55F91DED"><span class="cs5BCBAEC9">&sect;16-8C-1. West Virginia Prescription Drug Affordability Board established.</span></p><p class="cs45E53620"><span class="csF2E808A1">The purpose of the board is to protect West Virginia residents, state and local governments, commercial health plans, health care providers, pharmacies licensed in the state, and other stakeholders within the health care system from the high costs of prescription drug products.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-2. Definitions. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">For purposes of this article the following words have the meanings indicated.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Biologic&quot; means a drug that is produced or distributed in accordance with a biologics license application approved under 42 C.F.R. &sect; 447.502.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Biosimilar&quot; means a drug that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. &sect; 262(k)(3).</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Board&quot; means the West Virginia Prescription Drug Affordability Board.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Brand name drug&quot; means a drug that is produced or distributed in accordance with an original new drug application approved under 21 U.S.C. &sect; 355(c). &nbsp;&quot;Brand name drug&quot; does not include an authorized generic as defined by 42 C.F.R. &sect; 447.502.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Generic drug&quot; means:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) A retail drug that is marketed or distributed in accordance with an abbreviated new drug application, approved under 21 U.S.C. &sect; 355(j);</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) An authorized generic as defined by 42 C.F.R. &sect; 447.502; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) A drug that entered the market before 1962 that was not originally marketed under a new drug application.</span></p><p class="cs45E53620"><span class="csF2E808A1">&nbsp;&quot;Manufacturer&quot; means an entity that:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1)(A) Engages in the manufacture of a prescription drug product; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Enters into a lease with another manufacturer to market and distribute a prescription drug product under the entity&#39;s own name; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Sets or changes the wholesale acquisition cost of the prescription drug product it manufactures or markets.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Prescription drug product&quot; means a brand name drug, a generic drug, a biologic, or a biosimilar.</span></p><p class="cs45E53620"><span class="csF2E808A1">&quot;Stakeholder Council&quot; means the Prescription Drug Affordability Stakeholder Council.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-3. Board members. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a)(1) The board consists of the following members, who must have expertise in health care economics or clinical medicine:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) One member appointed by the Governor;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) One member appointed by the President of the Senate;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) One member appointed by the Speaker of the House of Delegates;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) One member appointed by the Attorney General; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) One member appointed by the Insurance Commissioner.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The board shall have the following alternate members, who must have expertise in health care economics or clinical medicine and who shall be designated by the board chair to participate in deliberations of the board when a member is recused:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) One alternate member appointed by the Governor;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) One alternate member appointed by the President of the Senate; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) One alternate member appointed by the Speaker of the House of Delegates.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) At least one member of the board shall have expertise in:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The 340B Program under the federal Public Health Service Act;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The state&#39;s All-Payer Claims Database;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) How the program and contract interact; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) How decisions made by the board will affect the model and contract.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) A member or an alternate member may not be an employee of, a board member of, or a consultant to a manufacturer, pharmacy benefits manager, health insurance carrier, health maintenance organization, managed care organization, or wholesale distributor or related trade association.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) Any conflict of interest, including whether the individual has an association, including a financial or personal association, that has the potential to bias or has the appearance of biasing an individual&#39;s decision in matters related to the board or the conduct of the board&#39;s activities, shall be considered and disclosed when appointing members and alternate members to the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(6) To the extent practicable and consistent with federal and state law, the membership of the board shall reflect the racial, ethnic, and gender diversity of the state.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b)(1) The term of a member or an alternate member is five years.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The terms of the members and alternate members are staggered and will be implemented as follows: </span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The first term of the member appointed by the Governor shall begin in 2025 and end in 2027, with every other term being five years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The first terms of the members appointed by the President of the Senate and the Speaker of the House shall begin in 2025 and end in 2028, with every subsequent term being five years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) The first term of the member appointed by the Attorney General shall begin in 2025 and end in 2029, with every other term being five years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) The first term of the member appointed by the Insurance Commissioner shall begin in 2025 and shall be five years in length, as shall all subsequent terms.</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) The first terms of the alternates shall match those of the primary members appointed by the same government official.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c)(1) The chair shall hire an executive director and staff for the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The chair shall develop a five-year budget and staffing plan and submit it to the board for approval.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Staff of the board shall receive a salary as provided in the budget of the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(d) A member of the board:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) May receive compensation as a member of the board in accordance with the state budget; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Is entitled to reimbursement for expenses under the reimbursement plans in effect at the Department of Health at that time.</span></p><p class="cs45E53620"><span class="csF2E808A1">(e)(1) The board shall meet in open session at least four times a year.</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) At the chair&#39;s discretion, the chair may cancel or postpone a meeting.</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The following actions by the board shall be made in open session:</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) The study required under &sect;16-8C-7;</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) Deliberations on whether to subject a prescription drug product to a cost review under &sect; 16-8C-8;</span></p><p class="cs45E53620"><span class="csF2E808A1">(iii) Any vote on whether to impose an upper payment limit on purchases and payor reimbursements of prescription drug products in the state; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(iv) Any decision by the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Notwithstanding the Open Meetings Act, the board may meet in closed session to discuss trade secrets or confidential and proprietary data and information. The board shall provide public notice of each board meeting in compliance with the Open Meetings Act, including notice of whether this is a public meeting.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Materials for each board meeting shall be made available to the public at least three days in advance of the meeting. Materials containing trade secrets or confidential and proprietary data or information that is not otherwise available to the public may not be made available to the public.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) The board shall provide an opportunity for public comment at each open meeting of the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) The board shall provide the public with the opportunity to provide written comments on pending decisions of the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(6) The board may allow expert testimony at board meetings, including when the board meets in closed session.</span></p><p class="cs45E53620"><span class="csF2E808A1">(7) To the extent practicable, the board shall access pricing information for prescription drug products by:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Entering into a memorandum of understanding with another state to which manufacturers already report pricing information; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Accessing other available pricing information.</span></p><p class="cs45E53620"><span class="csF2E808A1">(8) A majority of the members of the board constitutes a quorum.</span></p><p class="cs45E53620"><span class="csF2E808A1">(9) Members of the board shall recuse themselves from decisions related to a prescription drug product if the member, or an immediate family member of the member, has received or could receive any of the following:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) A direct financial benefit of any amount deriving from the result or finding of a study or determination by or for the board; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) A financial benefit from any person that owns, manufactures, or provides prescription drug products, services, or items to be studied by the board that in the aggregate exceeds $5,000 per year.</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) For the purposes of this section, a financial benefit includes honoraria, fees, stock, the value of the member&#39;s or immediate family member&#39;s stock holdings, and any direct financial benefit deriving from the finding of a review conducted under this subtitle.</span></p><p class="cs45E53620"><span class="csF2E808A1">(f) In addition to the powers set forth elsewhere in this subtitle, the board may:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Adopt regulations to carry out the provisions of this subtitle; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(g) Unless permission is granted by the board, a third party hired by the board in accordance with subsection (f)(2) of this section may not release, publish, or otherwise use any information to which the third party has access under its contract.</span></p><p class="cs45E53620"><span class="csF2E808A1">(h) The board is subject to the rules and policies of the Purchasing Division.</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) The Attorney General is the legal adviser to the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) The Attorney General shall designate an assistant attorney general as counsel to the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) As needed, the Attorney General may assign additional assistant attorneys general to the board to give effective legal advice and counsel.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) The counsel to the board may not have a duty other than to:</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) Give the legal aid, advice, and counsel required by the board;</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) Supervise the other assistant attorneys general assigned to the board, if any; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(iii) Perform for the board the duties that the Attorney General assigns.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) The counsel shall perform these duties subject to the control and supervision of the Attorney General.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) After the Attorney General designates the counsel to the board, the Attorney General may not reassign the counsel without consulting the board.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-4. Prescription Drug Affordability Stakeholder Council. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) There is a Prescription Drug Affordability Stakeholder Council.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) The purpose of the Stakeholder Council is to provide stakeholder input to assist the board in making decisions as required under this subtitle.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) The Stakeholder Council consists of 26 members appointed in accordance with this subsection.</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) The Speaker of the House of Delegates shall appoint:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) One representative of generic drug corporations;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) One representative of nonprofit insurance carriers;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) One representative of a statewide health care advocacy coalition;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) One representative of a statewide advocacy organization for seniors;</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) One representative of a statewide organization for diverse communities;</span></p><p class="cs45E53620"><span class="csF2E808A1">(F) One representative of a labor union;</span></p><p class="cs45E53620"><span class="csF2E808A1">(G) One health services researcher specializing in prescription drugs; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(H) One public member at the discretion of the Speaker of the House of Delegates.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The President of the Senate shall appoint:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) One representative of brand name drug corporations;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) One representative of physicians;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) One representative of nurses;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) One representative of hospitals;</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) One representative of dentists;</span></p><p class="cs45E53620"><span class="csF2E808A1">(F) One representative of managed care organizations;</span></p><p class="cs45E53620"><span class="csF2E808A1">(G) One representative of pharmacists;</span></p><p class="cs45E53620"><span class="csF2E808A1">(H) One clinical researcher; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(I) One public member at the discretion of the President of the Senate.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) The Governor shall appoint:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) One representative of brand name drug corporations;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) One representative of generic drug corporations;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) One representative of biotechnology companies;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) One representative of for-profit health insurance carriers;</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) One representative of employers;</span></p><p class="cs45E53620"><span class="csF2E808A1">(F) One representative of pharmacy benefits managers;</span></p><p class="cs45E53620"><span class="csF2E808A1">(G) One representative of the State Budget Office;</span></p><p class="cs45E53620"><span class="csF2E808A1">(H) One pharmacologist; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(I) One public member at the discretion of the Governor.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) Collectively, the members of the Stakeholder Council shall have knowledge of the following:</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) The pharmaceutical business model;</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) Supply chain business models;</span></p><p class="cs45E53620"><span class="csF2E808A1">(iii) The practice of medicine or clinical training;</span></p><p class="cs45E53620"><span class="csF2E808A1">(iv) Consumer or patient perspectives;</span></p><p class="cs45E53620"><span class="csF2E808A1">(v) Health care costs trends and drivers;</span></p><p class="cs45E53620"><span class="csF2E808A1">(vi) Clinical and health services research; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(vii) The state&#39;s health care marketplace.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) To the extent practicable and consistent with federal and state law, the membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity of the state.</span></p><p class="cs45E53620"><span class="csF2E808A1">(6) From among the membership of the Stakeholder Council, the board chair shall appoint two members to be cochairs of the Stakeholder Council.</span></p><p class="cs45E53620"><span class="csF2E808A1">(d)(1) The term of a member is 3 years.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The initial members of the Stakeholder Council shall serve staggered terms as follows:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The first term of the member appointed by the Governor shall begin in 2025 and end in 2027, with every other term being five years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The first terms of the members appointed by the President of the Senate shall begin in 2025 and end in 2027, with every subsequent term being three years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) The first terms of the members appointed by the President of the Senate shall begin in 2025 and end in 2027, with every subsequent term being three years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) The first terms of the members appointed by the Speaker of the House shall begin in 2025 and end in 2027, with every subsequent term being three years in length;</span></p><p class="cs45E53620"><span class="csF2E808A1">(e) A member of the Stakeholder Council:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) May not receive compensation as a member of the Stakeholder Council; but</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Is entitled to reimbursement travel in accordance with the state budget.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-5. Disclosure of conflicts of interest. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a)(1) A conflict of interest shall be disclosed:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) By the board when hiring board staff;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) By the appointing authority when appointing members and alternate members to the board and members to the Stakeholder Council; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) By the board, when a member of the board is recused in any final decision resulting from a review of a prescription drug product.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) A conflict of interest shall be disclosed:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) In advance of the first open meeting after the conflict is identified; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Within five days after the conflict is identified.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b)(1) A conflict of interest disclosed under this section shall be posted on the website of the board unless the chair of the board recuses the member from any final decision resulting from a review of a prescription drug product.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) A posting of the conflict of interest on the board&#39;s website shall include the type, nature, and magnitude of the interests of the member involved.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-6. Ethics of board members, staff, and third-party contractors. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">The board members, staff, and third-party contractors must adhere the West Virginia Public Employees&#39; Ethics Act.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-7. Study and report. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">On or before December 31, 2028, the board, in consultation with the Stakeholder Council, shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Study the entire pharmaceutical distribution and payment system in the state and policy options being used in other states and countries to lower the list price of pharmaceuticals, including:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Setting upper payment limits;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Using a reverse auction marketplace; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Implementing a bulk purchasing process; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Report its findings and recommendations and any legislation required to implement the recommendations, to the Governor and the Legislative Joint Committee on Government on Finance.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-8. Collection, review, and use of transparency data for prescription drug products. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) On or before December 31, 2028, the board shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Collect and review publicly available information regarding prescription drug product manufacturers, health insurance carriers, health maintenance organizations, managed care organizations, wholesale distributors, and pharmacy benefits managers; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Identify states that require reporting on the cost of prescription drug products; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Initiate a process of entering into memoranda of understanding with the states identified under &sect;16-8C-8(a)(2) to aid in the collection of transparency data for prescription drug products.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) Based on the information collected under this section and obtained through memoranda of understanding under this section, the board, in consultation with the stakeholder council, shall adopt regulations to:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Establish methods for collecting additional data necessary to carry out its duties under this subtitle; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Identify circumstances under which the cost of a prescription drug product may create or has created affordability challenges for the state health care system and patients.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) The board shall use the information collected under this section and obtained through memoranda of understanding under this section to identify prescription drug products that are:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Brand name drugs or biologics that, as adjusted annually for inflation in accordance with the Consumer Price Index, have:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) A launch wholesale acquisition cost of $30,000 or more per year or course of treatment; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) A wholesale acquisition cost increase of $3,000 or more in any 12-month period, or course of treatment if less than 12 months;</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Biosimilar drugs that have a launch wholesale acquisition cost that is not at least 15% lower than the referenced brand biologic at the time the biosimilars are launched;</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Generic drugs that, as adjusted annually for inflation in accordance with the Consumer Price Index, have a wholesale acquisition cost:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Of $100 or more for:</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) A 30-day supply lasting a patient for a period of 30 consecutive days based on the recommended dosage approved for labeling by the United States Food and Drug Administration;</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) A supply lasting a patient for fewer than 30 days based on the recommended dosage approved for labeling by the United States Food and Drug Administration; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(iii) One unit of the drug if the labeling approved by the United States Food and Drug Administration does not recommend a finite dosage; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) That increased by 200% or more during the immediately preceding 12-month period, as determined by the difference between the resulting wholesale acquisition cost and the average of the wholesale acquisition cost reported over the immediately preceding 12 months; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) Other prescription drug products that may create affordability challenges for the state health care system and patients, in consultation with the Stakeholder Council.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-9. Cost review of prescription drug products with affordability challenges. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a)(1) After identifying prescription drug products as required by &sect;16-8C-8, the board shall determine whether to conduct a cost review as described in subsection (b) of this section for each identified prescription drug product by:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Seeking Stakeholder Council input about the prescription drug product; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Considering the average cost share of the prescription drug product.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2)(A) To the extent there is no publicly available information to conduct a cost review as described in subsection (b) of this section, the board shall request the information from:</span></p><p class="cs45E53620"><span class="csF2E808A1">(i) The manufacturer of the prescription drug product; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) As appropriate, a wholesale distributor, pharmacy benefits manager, health insurance carrier, health maintenance organization, or managed care organization with relevant information on setting the cost of the prescription drug product in the state.</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The information to conduct a cost review may include any document and research related to the manufacturer&#39;s selection of the introductory price or price increase of the prescription drug product, including life cycle management, net average price in the state, market competition and context, projected revenue, and the estimated value or cost-effectiveness of the prescription drug product.</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Failure of a manufacturer, wholesale distributor, pharmacy benefits manager, health insurance carrier, health maintenance organization, or managed care organization to provide the board with the information requested under this paragraph does not affect the authority of the board to conduct a review as described in subsection (b) of this section.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b)(1) If the board conducts a review of the cost of a prescription drug product, the review shall determine whether use of the prescription drug product that is fully consistent with the labeling approved by the United States Food and Drug Administration or standard medical practice has led or will lead to affordability challenges for the state health care system or high out-of-pocket costs for patients.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) To the extent practicable, in determining whether a prescription drug product identified under &sect;16-8C-8 has led or will lead to an affordability challenge, the board shall consider the following factors:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The wholesale acquisition cost and any other relevant prescription drug cost index for the prescription drug product sold in the state;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The average monetary price concession, discount, or rebate the manufacturer provides to health plans in the state or is expected to provide to health plans in the state as reported by manufacturers and health plans, expressed as a percent of the wholesale acquisition cost for the prescription drug product under review;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) The total amount of the price concession, discount, or rebate the manufacturer provides to each pharmacy benefits manager operating in the state for the prescription drug product under review, as reported by manufacturers and pharmacy benefits managers, expressed as a percent of the wholesale acquisition costs;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) The price at which therapeutic alternatives have been sold in the state;</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) The average monetary concession, discount, or rebate the manufacturer provides or is expected to provide to health plan payors and pharmacy benefits managers in the state for therapeutic alternatives;</span></p><p class="cs45E53620"><span class="csF2E808A1">(F) The costs to health plans based on patient access consistent with United States Food and Drug Administration labeled indications;</span></p><p class="cs45E53620"><span class="csF2E808A1">(G) The impact on patient access resulting from the cost of the prescription drug product relative to insurance benefit design;</span></p><p class="cs45E53620"><span class="csF2E808A1">(H) The current or expected dollar value of drug-specific patient access programs that are supported by the manufacturer;</span></p><p class="cs45E53620"><span class="csF2E808A1">(I) The relative financial impacts to health, medical, or social services costs as can be quantified and compared to baseline effects of existing therapeutic alternatives;</span></p><p class="cs45E53620"><span class="csF2E808A1">(J) The average patient copay or other cost-sharing for the prescription drug product in the state; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(K) Any other factors as determined by the board in regulations adopted by the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) If the board is unable to determine whether a prescription drug product will produce or has produced challenges to the affordability of the drug for the state health care system, using the factors listed in paragraph (2) of this subsection, the board may consider the following factors:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The manufacturer&#39;s research and development costs, as indicated on the manufacturer&#39;s federal tax filing or information filed with the Federal Securities and Exchange Commission for the most recent tax year in proportion to the manufacturer&#39;s sales in the state;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The portion of direct-to-consumer marketing costs eligible for favorable federal tax treatment in the most recent tax year that are specific to the prescription drug product under review and that are multiplied by the ratio of total manufacturer in-state sales to total manufacturer sales in the United States for the product under review;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Gross and net manufacturer, pharmacy benefits manager, and wholesale distributor revenues for the prescription drug product under review for the most recent tax year;</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) Any additional factors proposed by the manufacturer and appropriate health insurance carriers, health maintenance organizations, managed care organizations, wholesale distributors, and pharmacy benefits managers that the board considers relevant; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(E) Any additional factors as established by the board in regulations.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) On or before December 31, 2026, and each December 31 thereafter, the board shall submit to the Governor and the Legislative Joint Committee on Government a report that includes:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Price trends for prescription drug products;</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The number of prescription drug products that were subject to board review and the results of the review; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Any recommendations the board may have on further legislation needed to make prescription drug products more affordable in the state.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-10. Confidentiality. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) All information and data obtained by the board under this subtitle, that is not otherwise publicly available:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Is considered to be a trade secret and confidential and proprietary information; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Is not subject to disclosure under the West Virginia Freedom of Information Act, &sect;29B-1-1 </span><span class="cs13A1C9D2">et seq</span><span class="csF2E808A1">. of this code.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) Only board members and staff may access trade secrets and confidential and proprietary data and information obtained under this subtitle that is not otherwise publicly available.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) The provisions of &sect;47-22-1, </span><span class="cs13A1C9D2">et seq.</span><span class="csF2E808A1"> of this code shall apply to any trade secrets and confidential and proprietary data and information obtained under this subtitle that is not otherwise publicly available.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-11. Funding source. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) In this section, &quot;fund&quot; means the Prescription Drug Affordability Fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b)(1) The board shall assess and collect an annual fee on:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Manufacturers that sell or offer for sale prescription drug products to persons in the state;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Pharmacy benefits managers, as defined in &sect;33-51-3;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Insurers and private insurance carriers, as defined in &sect;23-1-1, </span><span class="cs13A1C9D2">et seq</span><span class="csF2E808A1">. and &sect;33-1-1</span><span class="cs13A1C9D2">, et seq</span><span class="csF2E808A1">. of this code; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) Wholesale distributors, as defined in &sect;12-6C-01, that sell or offer for sale prescription drug products to persons in the state.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The board shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Assess and collect the annual fee under paragraph (1) of this subsection in accordance with criteria established in regulations adopted by the board; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Calculate the annual fee under paragraph (1) of this subsection in a fair and equitable manner.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3)(i) On or before October 1 each year, each entity assessed a fee under this subsection shall pay the fee assessed by the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(ii) The board shall allow entities to make partial payments when paying the fee assessed under this subsection.</span></p><p class="cs45E53620"><span class="csF2E808A1">(iii) Any fee not paid within 30 days after the payment due date may be subject to an interest penalty to be determined and collected by the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) The total amount of fees that the board collects in each calendar year under paragraph (1) of this subsection may not exceed $2,000,000.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) The board shall pay all fees collected under paragraph (1) of this subsection into the fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c)(1) There is a Prescription Drug Affordability Fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The purpose of the fund is to provide funding for the board and to carry out the purpose of this subtitle.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) The board shall administer the fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4)(A) The fund is a special, non-lapsing fund that shall not revert to the general fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The state Treasurer shall hold the fund separately.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) The fund consists of:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Revenue distributed to the fund under subsection (b) of this section;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Money appropriated in the state budget to the fund;</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Interest earnings; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(D) Any other money from any other source accepted for the benefit of the fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(6) The fund may be used only to provide funding for the board and for the purposes authorized under this subtitle, including administrative expenses and any costs expended by any state agency to implement this subtitle.</span></p><p class="cs45E53620"><span class="csF2E808A1">(7)(A) The State Treasurer shall invest the money of the fund in the same manner as other state money may be invested.</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) Any interest earnings of the fund shall be credited to the fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(8) Expenditures from the fund may be made only in accordance with the state budget.</span></p><p class="cs45E53620"><span class="csF2E808A1">(9) The fund is subject to audit by the Legislative Auditor.</span></p><p class="cs45E53620"><span class="csF2E808A1">(10) This subsection may not be construed to prohibit the fund from receiving funds from any other source.</span></p><p class="cs45E53620"><span class="csF2E808A1">(d)(1) The board shall be established using special or general funds, which shall be repaid to the state with the funds from the fund.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) If the board receives funding from the West Virginia Department of Health under paragraph (1) of this subsection, the board shall repay the funds to the commission from the fund over a three-year period beginning June 1, 2026.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-12. Enforcement. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">The Office of the Attorney General may pursue any available remedy under state law when enforcing this subtitle.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-13. Process for setting upper payment limits for prescription drug products. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) If, under &sect;16-8C-7, the board finds that it is in the best interest of the state to establish a process for setting upper payment limits for prescription drug products that it determines have led or will lead to an affordability challenge, the board, in conjunction with the Stakeholder Council, shall draft a plan of action for implementing the process that includes the criteria the board shall use to set upper payment limits.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) The criteria for setting upper payment limits shall include consideration of:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) The cost of administering the prescription drug product;</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The cost of delivering the prescription drug product to consumers; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Other relevant administrative costs related to the prescription drug product.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) The process for setting upper payment limits shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Prohibit the application of an upper payment limit for a prescription drug product that is on the federal Food and Drug Administration prescription drug shortage list; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Require the board to:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Monitor the availability of any prescription drug product for which it sets an upper payment limit; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) If there becomes a shortage of the prescription drug product in the state, reconsider or suspend the upper payment limit.</span></p><p class="cs45E53620"><span class="csF2E808A1">(d)(1) If a plan of action is drafted under subsection (a) of this section, the board shall submit the plan of action to the Legislative Oversight Commission on Health and Human Resources.</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) The Legislative Oversight Commission on Health and Human Resources shall have 45 days to approve the plan of action.</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) If the Legislative Oversight Commission on Health and Human Resources does not approve the plan of action, the board shall submit the plan to the Governor and the Attorney General for approval.</span></p><p class="cs45E53620"><span class="csF2E808A1">(4) The Governor and the Attorney General shall have 45 days to approve the plan of action.</span></p><p class="cs45E53620"><span class="csF2E808A1">(5) The board may not set upper payment limits unless the plan is approved, in accordance with this subsection, by:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) The Legislative Oversight Commission on Health and Human Resources; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) The Governor and Attorney General.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-14. Eligible drug products; limit amount; drug product availability. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) If a plan of action is approved under &sect;16-8C-13(d), the board may set upper payment limits for prescription drug products that are:</span></p><p class="cs45E53620"><span class="csF2E808A1">(1) Purchased or paid for by a unit of state or local government or an organization on behalf of a unit of state or local government, including:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) State or county correctional facilities;</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) State hospitals; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(C) Health clinics at state institutions of higher education;</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Paid for through a health benefit plan on behalf of a unit of state or local government, including a county, or municipal employee health benefit plan; or</span></p><p class="cs45E53620"><span class="csF2E808A1">(3) Purchased for or paid for by the West Virginia Department of Health.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) The upper payment limits set under subsection (a) of this section shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">&nbsp;(1) Be for prescription drug products that have led or will lead to an affordability challenge; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(2) Be set in accordance with the criteria established in regulations adopted by the board.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c)(1) The board shall:</span></p><p class="cs45E53620"><span class="csF2E808A1">(A) Monitor the availability of any prescription drug product for which it sets an upper payment limit; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(B) If there becomes a shortage of the prescription drug product in the state, reconsider whether the upper payment limit should be suspended or altered.</span></p><p class="cs45E53620"><span class="csF2E808A1">&nbsp;(2) An upper payment limit set under subsection (a) of this section may not be applied to a prescription drug product while the prescription drug product is on the federal Food and Drug Administration prescription drug shortage list.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-15. Remedies. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) A person aggrieved by an upper payment limit set by the board may request an appeal within 30 days after the board makes the decision to set the limit.</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) The board shall hear the appeal and make a final decision within 60 days after the appeal is requested.</span></p><p class="cs45E53620"><span class="csF2E808A1">(c) Any person aggrieved by a final decision of the board issued under subsection (b) of this section may petition for judicial review.</span></p><p class="cs5AD36D8A"><span class="cs5BCBAEC9">&sect;16-8C-16. Report. </span></p><p class="cs45E53620"><span class="csE736517A">&nbsp;</span></p><p class="cs45E53620"><span class="csF2E808A1">On or before December 1, 2028, the board, in consultation with the stakeholder council, shall report to the Legislative Oversight Commission on Health and Human Resources Accountability:</span></p><p class="cs45E53620"><span class="csF2E808A1">(a) The legality, obstacles, and benefits of setting upper payment limits on all purchases and payor reimbursements of prescription drug products in the state; and</span></p><p class="cs45E53620"><span class="csF2E808A1">(b) Recommendations regarding whether the Legislature should pass legislation to expand the authority of the board to set upper payment limits to all purchases and payor reimbursements of prescription drug products in the state.</span></p><p class="csDE8452F9"><span class="csAD690475">&nbsp;</span></p><p class="csDE8452F9"><span class="csAD690475">NOTE: The purpose of this bill is to establish the West Virginia Prescription Drug Affordability Board; provide definitions; provide for the creation of a Board and the composition, compensation, and duties associated with the Board; provide for the creation of a stakeholder council and the composition, and duties associated with the Council; &nbsp;provide disclosures of conflicts of interest and requiring adherence to the Ethics Act; require a study and report on transparency data on prescription drug products; provide a cost review of prescription drug products with affordability challenges; require confidentiality; establish a fund; provide for enforcement; clarify drug products eligible; provide remedies; and list all report requirements.</span></p><p class="csDE8452F9"><span class="csAD690475">Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.</span></p>


</div>
 
 
</div><!--wrapper-->


<div id="footer">

<div class="footerlinks">
<a href="/bill_status/bill_status.cfm">Bill Status</a>&nbsp;&nbsp;|&nbsp;
<a href="/billstatus_personalized/persbills_login.cfm">Bill Tracking</a>&nbsp;&nbsp;|&nbsp;
<a href="/wvcodeentire.htm">Legacy WV Code</a>&nbsp;&nbsp;|&nbsp;
<a href="https://www.wvlegislature.gov/Bulletin_Board/Bulletin_Board_menu.cfm">Bulletin Board</a>&nbsp;&nbsp;|&nbsp;
<a href="/redistricting.cfm">District Maps</a>&nbsp;&nbsp;|&nbsp;
<a href="/Senate1/roster.cfm">Senate Roster</a>&nbsp;&nbsp;|&nbsp; 
<a href="/House/roster.cfm">House Roster</a>&nbsp;&nbsp;|&nbsp;
<a href="/live.cfm">Live</a>&nbsp;&nbsp;|&nbsp;
<a href="//blog.wvlegislature.gov/">Blog</a>&nbsp;&nbsp;|&nbsp;
<a href="//jobs.wvlegislature.gov/">Jobs</a>&nbsp;&nbsp;|&nbsp; 
<a href="/Contact/Links/links.cfm">Links</a>&nbsp;&nbsp;|&nbsp;
<!--<a href="/FAQs/FAQ.cfm">FAQ</a>&nbsp;&nbsp;|&nbsp;
<a href="/site_map.cfm">Site Map</a>&nbsp;&nbsp;|&nbsp;-->
<a href="/index.cfm">Home</a>
</div>
<div class="social">
<span>
</a>
<a href="https://www.facebook.com/wvlegislature"><img src="/images/SOCIAL-ICON-SET/512x512/facebook.png" alt="Find on Facebook" width="24" height="24" align="absmiddle" title="Find on Facebook"></a>
<a href="https://twitter.com/wvlegislature"><img src="/images/SOCIAL-ICON-SET/512x512/twitter.png" alt="Follow on Twitter" width="24" height="24" align="absmiddle" title="Follow on Twitter"></a>
<a href="https://www.youtube.com/wvlegislature/"><img src="/images/SOCIAL-ICON-SET/512x512/utube.png" alt="Watch on YouTube" width="24" height="24" align="absmiddle" title="Watch on YouTube"></a>
</span>
</div>
</div>
<div class="baseline">This Web site is maintained by the <a href="/Joint/legisinfo.cfm">West Virginia Legislature's Office of Reference &amp; Information.</a> &nbsp;|&nbsp; <a href="/termsofuse.cfm"> Terms of Use</a>  &nbsp;| &nbsp; <a href="mailto:webmaster@wvlegislature.gov"> <img src="/images/mail_icon.png" alt="Email Webmaster" align="top" title="Email Webmaster">Webmaster</a> &nbsp;  | &nbsp;  &copy; 2025 West Virginia Legislature  ** 
</div><br /><br />

<div id='pod-popup' class='noprint'>
	<a class="b-close"><img src='/js/images/close-icon128x128.png' alt='X'></a>
	<h3>Print On Demand</h3>
	<div class='pod-meta'>Name:<input type='text' value='' id='pod-name' class='meta-input'></div>
	<div style='clear:both'></div>
    <div class='pod-meta'>Email:<input type='text' value='' id='pod-email' class='meta-input'></div>
	<div style='clear:both'></div>
    <div class='pod-meta'>Phone:<input type='text' value='' id='pod-phone' class='meta-input'></div>
	<div style='clear:both'></div>
	<div id='pod-content'></div>
	<hr>
	<a><img id='pod-go' src='/js/images/print-request159x50.png' alt='Print'></a>
</div>
<script>
	$('div.textcontainer a').replaceWith(function(){
		return this.childNodes;
	});
</script>
<script type="text/javascript" src="/js/validcodecheck.js"></script>
<script type="text/javascript" src="/js/pod.js"></script>
<script type="text/javascript" src="/js/codedetect.js"></script>
<script type="text/javascript" src="/js/cleanfiscalnote.js"></script>
</body>
</html>